Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections | CMAC

Cefpodoxime proxetil – new opportunities in antibacterial therapy of respiratory infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2023; 25(4):366-371

Section
Type
Expert opinion

Abstract

The purpose of the expert council was to determine the place of cefpodoxime in the ABT algorithms for upper and lower respiratory tract infections and to form a consensus position on its use in clinical practice. Based on the available data, the possibility of including cefpodoxime in national guidelines for the treatment of rhinosinusitis, acute tonsillopharyngitis, community-acquired pneumonia (CAP), as well as infectious exacerbations of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) is being considered.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared